Phathom Pharmaceuticals (PHAT) Gains from Investment Securities (2019 - 2026)
Phathom Pharmaceuticals (PHAT) reported Gains from Investment Securities of $171000.0 for Q1 2026, up 109.45% year-over-year from $81643.4 in Q1 2025, and up 103.22% quarter-over-quarter from -$5.3 million in Q4 2025.
Phathom Pharmaceuticals (PHAT) Gains from Investment Securities (2019 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 8 years of Gains from Investment Securities data on file, last reported at $171000.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $171000.0, up 109.45% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.7 million (down 542.15% YoY), and the FY2025 annual result was $9.4 million, up 53.37% from the prior year.
- Gains from Investment Securities climbed to $171000.0 in Q1 2026 per PHAT's latest filing, from -$5.3 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $9.7 million in Q2 2025 and troughed at -$5.3 million in Q4 2025.
- A 5-year average of $1.3 million and a median of $171000.0 in 2026 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2023 and 2024: Gains from Investment Securities sank 205500.0% in 2023, then surged 6639.38% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at -$1000.0 in 2022, then slumped by 205500.0% to -$2.1 million in 2023, then jumped by 304.38% to $4.2 million in 2024, then sank by 226.25% to -$5.3 million in 2025, then surged by 103.22% to $171000.0 in 2026.
- Business Quant data shows PHAT's Gains from Investment Securities at $171000.0 in Q1 2026, -$5.3 million in Q4 2025, and $9.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Phathom Pharmaceuticals | 895.99 Mn | 712.23 Mn | 46.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 171,000.00 |
| Mar 31, 2026 | 171,000.00 |
| Dec 31, 2025 | -5.31 Mn |
| Dec 31, 2025 | -5.31 Mn |
| Sep 30, 2025 | 9.45 Mn |
| Sep 30, 2025 | 9.45 Mn |
| Jun 30, 2025 | 9.67 Mn |
| Jun 30, 2025 | 9.67 Mn |
| Mar 31, 2025 | -1.81 Mn |
| Mar 31, 2025 | -1.81 Mn |
| Dec 31, 2024 | 4.20 Mn |
| Dec 31, 2024 | 4.20 Mn |
| Sep 30, 2024 | 2.24 Mn |
| Sep 30, 2024 | 2.24 Mn |
| Jun 30, 2024 | 2.22 Mn |
| Jun 30, 2024 | 2.22 Mn |
| Mar 31, 2024 | 159,666.00 |
| Mar 31, 2024 | 159,666.00 |
| Dec 31, 2023 | -2.06 Mn |
| Dec 31, 2023 | -2.06 Mn |